anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND Jejunal diverticulosis are false diverticula of the small bowel that form from outpouching of the mucosa and submucosa. They are pulsion diverticula that are often asymptomatic and can be found incidentally during surgery. In some instances, jejunal diverticula could result in intestinal obstruction. Small intestinal volvulus is an uncommon cause of small bowel obstruction that results in a closed loop obstruction and is an indication for emergent surgical intervention. CASE REPORT We report a case of an 84-year-old man who presented to the Emergency Department with abdominal pain and generalized weakness. A preoperative computerized tomographic scan demonstrated a closed loop small bowel obstruction with mesenteric swirling. The patient was taken for a diagnostic laparoscopy, which revealed extensive proximal jejunal diverticulosis and a volvulus of the involved jejunum. An exploratory laparotomy was warranted for safe detorsion of the small bowel and resection of the diseased segment. The small bowel was successfully detorsed, with resection of the involved jejunum. Intestinal continuity was established by a primary side-to-side anastomosis. CONCLUSIONS Jejunal diverticula have been reported in the literature as a cause of small bowel obstructions, and very few reports exist of concurrent small bowel volvulus. In very rare instances, both of these conditions can coexist. There should be prompt surgical intervention in all cases of closed loop small bowel obstructions to prevent intestinal ischemia, perforation, and sepsis.
Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.
Increased susceptibility to infection and the possible development of lymphoma and other malignancies, particularly of the skin, may result from immunosuppression. The rates of lymphoma/lymphoproliferative disease observed in Studies 1 and 2 were 0.7–3.2% (for Rapamune-treated patients) versus 0.6–0.8% (azathioprine and placebo control) [see Adverse Reactions (6.1) and (6.2)]. Oversuppression of the immune system can also increase susceptibility to infection, including opportunistic infections such as tuberculosis, fatal infections, and sepsis. Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should use Rapamune for prophylaxis of organ rejection in patients receiving renal transplants. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.
The invention discloses a fatigue response testing and evaluating method for civil aviation mental practitioners. Firstly, constructing a reaction level test index of civil aviation brain practitioners; designing test categories according to the reaction level test indexes of the civil aviation brain practitioners, analyzing and evaluating the test data in each test category, finally calculating and determining the proportion of the test result of each test category through the statistics of the evaluation index data, and determining the fatigue reaction level of the civil aviation brain practitioners according to the proportion of the test result. The method can reduce the possibility of potential safety hazard caused by human factors to the minimum. The reaction level of the civil aviation mental practitioner after fatigue is visually embodied in a numerical form, and the method has higher usability compared with the past achievements. The 5 tests have the obvious characteristic of simple and convenient implementation, and solve the problems of large volume, high cost, complexity, inconvenience and the like of test equipment in the past results. The method can be used for supervising the fatigue state of civil aviation mental practitioners, and has a good market promotion space.
In this study the oesophageal Doppler monitor (CardioQ+), arterial pulse wave analysis (via the CardioQ+ and Flotrac device) and central venous pressure (CVP) will be used to estimate mean systemic filling pressure (MSFP) with the inspiratory hold method. Furthermore the MSFParm will be determined using a rapid cuff inflator. From MSFP vascular compliance (Csys) and stressed volume (Vs) will be calculated.

The accuracy of Vs to follow a 500 increase in volume will be studied. The accuracy of MSFP and Vs to to predict fluid loading responsiveness will be assessed in 42 patients after elective coronary artery bypass grafting (CABG) surgery. The effect of a standardised fluid loading on parameters of intrinsic contractility and afterload will be determined. The effect of fluid loading on inertia, resistance and elastance will be assessed
No intervention will be applied. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to monitor health status.
Sedation is an integral part of modern intensive care medicine and has seen a tremendous development throughout the last years. Current guideline recommendations are targeted at an awake critically ill patients (target Richmond Agitation-Sedation Scale 0/-1) as early deep sedation has been shown to negatively affect the outcome. Nevertheless, is an adequate and individualized anxiolysis still an important intervention that can be achieved via process optimization, modifications to the infrastructure of the ward and pharmacologic therapy. Bolus application of benzodiazepines is a recommended pharmacologic measure to achieve proper anxiolysis. Midazolam is currently the most commonly used benzodiazepine in European intensive care units. Midazolam accumulates after repetitive application due to its pharmacokinetic properties, which increases the likelihood for side effects and makes targeted sedation increasingly difficult. Lormetazepam is used with increasing frequency as it is eliminated independent of the patients age and has few relevant metabolites. It is therefore thought to be better suited for targeted sedation management, which in turn would be beneficial for the patients.

The aim of this retrospective cohort study is to evaluate the effect of lormetazepam versus midazolam on hospital mortality, intensive care unit outcomes and sedation management.
Recently modified diagnostic criteria for chronic myelomonocytic leukaemia (CMML) have lowered the cut-off for absolute monocytosis. In the largest series to date, we have analysed 313 CMML patients, including 104 with oligomonocytic (OM)-CMML. Five-year survival was longer for OM-CMML than for other patients (p < 0.001). Multivariate analysis identified OM-CMML as a favourable prognostic factor (HR 0.58; p = 0.002). The 5-year cumulative incidence of progression to classical CMML was 47%. Older age and transfusion dependence were adverse prognostic factors for OM-CMML. Our results support the inclusion of OM-CMML in the CMML category as a subtype with superior outcomes.
PURPOSE: To obtain a skin preparation for external use excellent in the prevention and the improvement of rough skin and further having beautifying effect by concomitantly using specific two different materials excellent in safety. CONSTITUTION: One or more than one kind selected from tranexamic acid, its salts and its derivatives is compounded with nordihydroguaiaretic acid of the formula. Tranexamic acid, its salt or its derivative and nordihydroguaiaretic acid of the formula are preferably compounded in 0.1-5.0wt.% and 0.1-5.0wt.%, respectively. This skin preparation for external use is extremely effective against proliferative pachymenia, dry skin associated with erythema and a desquamative change of skin condition, and further effectively prevents and improves pigmentation. An example of the salt of tranexamic aid is its salt of a metal such as Mg, Ca or K or its sulfate, etc. The example of the derivative is a vitamin ester such as a vitamin A ester.
The present invention is a companion unit and companion system. The companion unit comprises an UAV that further comprises one or more of the following elements: propulsion units, circuit boards, navigation sensors, cameras, speakers, microphones, chassis, processors, and batteries. The companion system comprises one or more bases wirelessly connected to the companion unit and possibly to one or more computer devices and/or to the Internet. The elements thereby facilitate one or more of the following Internet connectivity, wireless local area network (WiFi) connectivity, computer device connectivity (e.g. connectivity to a cell phone, a smart phone, a laptop, a tablet, a smart television, a WiFi enabled appliance, or any other computer device), base connectivity, and cloud storage connectivity. The companion system and/or the companion unit is connected to an artificial intelligence module. The companion unit and system are programmed to function as a companion to a human user.
A device is provided for reliably, comfortably and conveniently introducing agents, including drugs and other substances, into the vaginal canal.  A discharge collection device (10) is also disclosed.  The disclosed devices may be formed of an elastomeric rim (11) and a flexible film.  The rim may have a non-circular cross section (406).  The film may be collapsible into a low profile insertion configuration.  The devices may be disposable, and are constructed to be convenient to use and comfortable to wear internally.  Preferably, the devices are formed from a thermoplastic material that softens in response to body temperature to provide improved comfort and handling. Although the rim (252") has a generally figure-eight-shaped cross-sectional configuration, it may have other cross-sectional configurations.  For example, the encapsulating material (406) (surrounding the O-rings 402, 404) may be provided with the D-shaped cross-sectional configuration of the rim (252').
Subjects will be prescribed with orthokeratology lenses which will be replaced at least every 12 months during the study period. They will be required to perform both daily cleaning and weekly protein removal for their lenses.
The role of measurable residual disease (MRD) negativity as a biomarker to stop treatment is being investigated in transplant-eligible patients with multiple myeloma (MM). Thus, it is important to identify risk factors of MRD resurgence and/or progressive disease (PD) among patients achieving undetectable MRD to avoid undertreating them. Here, we studied 267 newly diagnosed transplant-eligible patients with MM enrolled in the GEM2012MENOS65 and GEM2014MAIN clinical trials who achieved MRD negativity by next-generation flow cytometry. After a median follow-up of 73 months since the first MRD negative assessment, 111 of the 267 (42%) patients showed MRD resurgence and/or PD. The only prognostic factors at diagnosis that predicted MRD resurgence and/or PD were an International Staging System (ISS) 3 and the presence of ≥0.01% circulating tumor cells (CTCs). Failure to achieve MRD negativity after induction also predicted higher risk of MRD resurgence and/or PD. Patients having 0 vs 1 vs ≥2 risk factors (ISS 3, ≥0.01% CTCs, and late MRD negativity) showed 5-year rates of MRD resurgence and/or PD of 16%, 33%, and 57%, respectively (P < .001). Thus, these easily measurable risk factors could help refine the selection of patients for whom treatment cessation after MRD negativity is being investigated in clinical trials. This trial was registered at www.clinicaltrials.gov as NCT01916252 and NCT02406144.
The control group consumed 3 cups a day of Wissotzky- kid drink (Wissotzky Tea Israel Ltd), which is a drink that is marketed for children containing an infusion of fruits and plants. Each tea bag contains 2.7 gr plants parts with no evidence of polyphenols or caffeine.
Group B will be injected with 20 ml of 0. 25% bupivacaine in each side added to it dexmedetomidine 0.5 μg/kg; (Precedex 100 μg/ml (Hospira, inc, lake forest, USA).
The present invention provides an anti-hypertrophic compound comprising effective amount of 17?H-neriifolin extracted from Cerbera odollam. The compound of the present invention exhibit anti-hypertrophic effects on cardiomyocite cells even at small concentration. The present invention is found to reduce the size of hypertrophied cardiomycte cells and supressed the expressions of proteins iNOS, ROS, NO, NFKB. These proteins are reported to be involved in exerting hypertrophy effect of this cardiac cells. Thus, the present invention has potential towards drug development for management of heart failure. (Figure 1)
Following 3 months of data collection (pre-cohort group), education regarding the documented intervertebral space versus the actual intervertebral space that the neuraxial anesthetic was administered will be provided to each anesthesiologist and resident. Following delivery of this information, an additional 3 months of data collection will be performed (post-cohort group) (the same as the first 3 months) to evaluate whether a practice change took place.
Cases of secondary exposure resulting in virilization of children have been reported in postmarketing surveillance. Signs and symptoms have included enlargement of the penis or clitoris, development of pubic hair, increased erections and libido, aggressive behavior, and advanced bone age. In most cases, these signs and symptoms regressed with removal of the exposure to testosterone gel. In a few cases, however, enlarged genitalia did not fully return to age-appropriate normal size, and bone age remained modestly greater than chronological age. The risk of transfer was increased in some of these cases by not adhering to precautions for the appropriate use of the topical testosterone product. Children and women should avoid contact with unwashed or unclothed application sites in men using testosterone gel 1% [see Dosage and Administration (2.2), Use in Specific Populations (8.1), and Clinical Pharmacology (12.3)]. 

Inappropriate changes in genital size or development of pubic hair or libido in children, or changes in body hair distribution, significant increase in acne, or other signs of virilization in adult women should be brought to the attention of a physician and the possibility of secondary exposure to testosterone gel should also be brought to the attention of a physician. Testosterone gel should be promptly discontinued until the cause of virilization has been identified.
Management of immune thrombocytopenia (ITP) in dogs and cats is evolving, but there are no evidence-based guidelines to assist clinicians with treatment decisions. Likewise, the overall goals for treatment of ITP have not been established. Immunosuppressive doses of glucocorticoids are the first line treatment, but optimal treatment regimens beyond glucocorticoids remain uncertain. Additional options include secondary immunosuppressive drugs such as azathioprine, modified cyclosporine, and mycophenolate mofetil, usually selected based on clinician preference. Vincristine, human IV immunoglobulin (hIVIg), and transfusion of platelet or red blood cell-containing products are often used in more severe cases. Splenectomy and thrombopoietin receptor agonists are usually reserved for refractory cases, but when and in which patient these modalities should be employed is under debate. To develop evidence-based guidelines for individualized treatment of ITP patients, we asked 20 Population Intervention Comparison Outcome (PICO) format questions. These were addressed by 17 evidence evaluators using a literature pool of 288 articles identified by a structured search strategy. Evidence evaluators, using panel-designed templates and data extraction tools, summarized evidence and created guideline recommendations. These were integrated by treatment domain chairs and then refined by iterative Delphi survey review to reach consensus on the final guidelines. In addition, 19 non-PICO questions covering scenarios in which evidence was lacking or of low quality were answered by expert opinion using iterative Delphi surveys with panelist integration and refinement. Commentary was solicited from multiple relevant professional organizations before finalizing the consensus. The rigorous consensus process identified few comparative treatment studies, highlighting many areas of ITP treatment requiring additional studies. This statement is a companion manuscript to the ACVIM Consensus Statement on the Diagnosis of Immune Thrombocytopenia in Dogs and Cats.
Participants in this arm will undergo One Anastomosis Gastric Bypass surgery with the bypass performed at a distance of 200 centimeters from the duodenojejunal junction. This approach prioritizes maximizing weight loss but may carry a higher risk of nutritional deficiencies due to the longer bypass length. Postoperative outcomes will be evaluated for weight loss, total weight loss percentage, excess weight loss percentage, and nutritional markers, including albumin, calcium, and iron levels.
The invention belongs to the technical field of biology, and particularly discloses a fish source anion antibacterial peptide Lc149 and application thereof. The amino acid sequence of the fish source anion antibacterial peptide Lc149 is shown as SEQ ID NO.2, and the nucleotide sequence of the encoding gene is shown as SEQ ID NO. 1. The applicant obtains the fish source anion antibacterial peptide Lc149 by constructing a prokaryotic expression vector, inducing expression, crushing by ultrasonic waves and purifying. The antibacterial peptide Lc149 not only can inhibit the growth of escherichia coli, vibrio harveyi and bacillus subtilis, but also has the effect of killing ciliates of the shield; the antibacterial activity is not affected at 25-100deg.C. In addition, lc149 is non-hemolytic toxic to blood cells of large yellow croaker, shrimp and rabbits. The antibacterial peptide Lc149 can be used for biological control of bacterial and parasitic diseases of aquatic and mammals, or can be used as an antibacterial agent, an insecticide and a feed additive.
Vaccine potency is typically evaluated using an assay that acts as a surrogate for biological activity. Although in vivo vaccines better represent human immunological responses, in vitro assays are preferred due to lower variability, higher throughput, easier validation and ethical considerations. In in vitro determination of Human Papillomavirus (HPV), Virus-like particle (VLP) vaccine potency currently depends on monoclonal antibody assays. However, these reagents are hard to obtain and currently are not available commercially. In this work, a polyclonal antiserum-based immunoassay was developed to evaluate the relative potency of Alhydrogel formulated HPV 16 VLPs. The repeatability and specificity were evaluated, and found that the assay was sensitive to small amounts of non-VLP HPV 16 L1 proteins. Finally, the assay was tested in comparison to the mouse effective dose 50 (ED50) assay on a limited number of batches. The agreement between these results suggests this test as a suitable surrogate for the in vivo test.
A process for the preparation of an alcohol-free aerosol anti-perspirant powder spray composition includes the steps of dispersing a particulate aluminium compound in a liquefied gaseous propellant, passing the dispersion through a screen and packaging the screened dispersion in an aerosol container.  The aluminium compound may be the chlorhydrate, sulphate or chloride.  It is preferred to use as dispersing agent an ester such as isopropyl myristate or palmitate, stearyl palmitate or propylene glycol mono-oleate, or mixtures thereof.  The propellant may be a chlorofluorinated hydrocarbon or mixture of these, and the composition may also include a germicide and a perfume.  The aperture size of the screen is preferably less than 74 microns, more preferably less than 44 microns.ALSO:A process for the preparation of an alcohol-free aerosol antiperspirant powder spray composition includes the steps of dispersing a particulate aluminium compound in a liquefied gaseous propellant, passing the dispersion through a screen and packaging the screened dispersion in an aerosol container.  The aluminium compound may be the chlorhydrate, sulphate or chloride. It is preferred to use as dispersing agent an ester such as isopropyl myristate or palmitate, stearyl palmitate or propylene glycol mono-oleate, or mixtures thereof.  The propellant may be a chlorofluorinated hydrocarbon or mixture of these, and the composition may also include a germicide and a perfume.  The aperture size of the screen is preferably less than 74 microns, more preferably less than 44 microns.
Acupressure group Acupressure application will be applied twice a week, 24 times in total in 12 weeks. Each acupressure point will be massaged for 30 seconds to provide circulation before compression. After the massage, pressures will be applied consecutively for 90 seconds. The session duration for each woman will be 8 minutes in total, with 2 minutes for each point in each attempt.
The present invention relates to crystalline forms of 11 ß-(4-acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17.alpha.-pregna-4,9-dien-3-one. In particular, the invention relates to two crystalline ansolvate/anhydrate forms of this compound, polymorphs I and II. However, the present invention also relates to crystalline solvates, for example, methanol and ethanol solvates of 11 ß-(4-acetylphenyl)- 20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17.alpha.-pregna-4,9-dien-3-one, as precursors for the preparation of these two polymorphs I and II. Processes are described for the preparation of polymorph I by means of displacement crystallization or by means of extraction. The choice of the last solvent, before the ansolvate formation can take place, on the basis of the differences in the purification ratios of the individual solvates of 11 ß-(4-acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17.alpha.-pregna-4,9-dien-3-one is described. Polymorph I, according to the invention, is particularly suitable for the preparation of drugs.